We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
The DNA ID platform is a community marketplace for genomics research. The app allo...
The DNA ID platform is a community marketplace ...
Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical ...
Fortress Biotech ("Fortress" or "the Company") ...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. ...
CytomX Therapeutics develops Probody⢠therape...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.